IL-6 or IL-6R genetic polymorphisms have been reported to be associated with risk or prognosis in patients with some cancers (DeMichele et al., 2009; Motoyama et al., 2012; Stephens et al., 2012; Kibe et al., 2014; Ruzzo et al., 2014; Zhang et al., 2017; Gu et al., 2023). This evidence concerns the gene IL6R and cancer.